Cell Line Derived Xenografts (CDX) Tumor Microarrays (TMAs)
Leverage Tumor Microarrays (TMAs) for Precision Oncology Research
At Crown Bioscience, our CDX Tumor Microarrays (TMAs) are designed to provide researchers with high-quality, homogeneous tumor samples for comprehensive cancer research. These CDX TMAs facilitate high-throughput analysis, essential for biomarker discovery, drug target validation, and translational studies.
Our CDX TMA Catalog Includes:
| NAME | CATALOG # |
|---|---|
| Cell Line Derived Xenograft models – mixed cancer types TMA009 | TMA-CP-MX-009 |
| Cell Line Derived Xenograft models – mixed cancer types TMA010 | TMA-CP-MX-010 |
Sorry, no posts matched your criteria.
Why Choose Crown Bioscience’s CDX Tumor Microarrays?
- Uniformity and Quality: Homogeneous tumor samples ensure reliable and reproducible results.
- High-Throughput Analysis: Enables efficient large-scale studies across various cancer types.
- Essential for Research: Crucial for the discovery of novel biomarkers and validation of therapeutic targets.
For more information about our CDX TMAs or to discuss your research needs, please contact us.
Related Services
Digital Pathology Services
Advanced Pathology Services for Fast, Reliable Data: Histopathology, IHC, IF, and In Situ Hybridization with Automated Precision
Nanostring Spatial Transcriptomics and Proteomics Services
Explore the complete transcriptome and over 570 protein targets individually or in tandem, utilizing a range of sample inputs including whole tissue sections, tissue microarrays (TMAs), or organoids.
